Then his mother, Alia Hayes, got some bad news. The manufacturer, GSK, was going to stop manufacturing the brand-name ...

GSK Plc acquired an experimental drug from Chinese biotech firm Chimagen Biosciences for as much as $850 million, adding to ...

GSK said Wednesday that core operating profit increased five percent in the third quarter. "Strong growth in specialty medicines helped to offset lower vaccine sales and reflected successful new ...

Haleon missed third-quarter revenue and profit expectations on Thursday, hit by a stronger pound and lower sales of its ...

GSK cut its full-year vaccine sales outlook after key shots for respiratory syncytial virus and shingles missed expectations ...

GSK has stopped (PDF) development of one of the lead programs from its $2.1 billi | GSK has stopped development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 ...

GSK reiterated its full-year guidance after its new HIV and cancer treatments lifted profit ahead of analysts’ expectations ...

Strong growth in specialty medicines helped to offset lower vaccine sales and reflected successful new product launches in oncology and HIV, as well as the resilience we have now built into GSK's ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

GSK is delivering consistent financial performance ... 14,000,15,000 people die every year in America. This is a brand-new vaccine with a cautious ACIP, but we are in their hands in terms of ...

GlaxoSmithKline Pharmaceuticals reports a 16% jump in Q2 net profit to Rs 252 crore, driven by strong sales across segments.